“…Recently, we examined the antitumor and antiangiogenesis activities of the 5-FU-based drug, S-1 (1 mol/L teagaful, 0.4 mol/L 5-chloro-2,4-dihydroxypyridine, and 1mol/L potassium oxonate), at a sub-maximum tolerated dose (sub-MTD) on human colorectal cancer xenografts. The up-regulation of thrombospondin-1 (TSP-1), as well as down-regulation of microvessel formation, has been shown (5). However, the molecular basis for the suppression of angiogenesis by 5-FU has not been fully elucidated (6).…”